Averix Bio

A cGMP 21 CFR Parts 210/211 & ICH Q7 compliant cannabinoid extraction company producing API Phytocan

02/23/2022

Big news from Averix Bio!

Our Drug Master File (DMF) # MF036798 has been issued by the US Food & Drug Administration, US FDA, for our API phytocannabinoid CBD Isolate!

Averix Bio continues to set the compliance standard within the cannabis industry. This submission reinforces our commitment to supplying the highest quality ingredients for commercial applications, research, and clinical trials within the pharmaceutical, veterinary, cosmetics, and nutraceutical markets.

Compliance, consistency, and manufacturing rigor are the components that separate good products from great products. At Averix, great API ingredients are the core of our business. That's what sets us apart.
We look forward to talking with you about how Averix Bio is the ingredient supplier you've been looking for. We'll help you take your products to the next level. See our full press release below and reach out to learn more! hello@averixbio.com

Press Release: https://lnkd.in/dqSSaKk2

**p

12/30/2021

Averix is honored to be chosen by Alterola Biotech, a U.K.-based pharmaceutical company, to provide our API Phytocannabinoid CBD Isolate for their research, development, and manufacturing operations.

The company is focused on harnessing the therapeutic potential of cannabinoids and similar compounds to bring safe and efficacious treatments to seriously ill patients. In its news release announcing the agreement, Tim Rogers, Executive Chairman of Alterola Biotech, said “We are excited at the opportunity for Averix Bio to supply Alterola with GMP-compliant Active Pharmaceutical Ingredients (APIs) for our existing portfolio of cannabinoid development candidates.”

Learn more here: https://lnkd.in/gSZ2P-Wq

If you're ready to talk to a Tier One cannabinoid ingredient supplier you can trust, please get in touch with us at hello@averixbio.com or +1 252.220.0887, and let's start the conversation.

**p

11/10/2021

If you're attending Cannabis Europa in London this week, I'd love to schedule a time for us to talk about how our 21CFR Parts 210/211 cGMP-compliant cannabinoid ingredients can improve your products. Please contact me via email at daniel@averixbio.com.

Daniel Wadsworth
Business Director, N.A. & EMEAR

P.S. We also now offer an cGMP-compliant API Phytocannabinoid CBD Isolate for your and production.

**pindustry **p

11/09/2021

If your company is interested in exploring the human endocannabinoid system and how it processes cannabinoid ingredients for human health, we’d be honored to serve as your research partner and provide you with our cGMP-compliant API Phytocannabinoid CBD isolate.

Note: We successfully completed an independent audit by ProPharma Group in October and are ready to be your trusted partner Tier One supplier. Meet up with us at CPhI Worldwide this week or get in touch at hello@averixbio.com or +1 252.220.0887.

**p

11/03/2021

ATTN CPhI Attendees: Click here to schedule a get-together in Milan: https://bit.ly/3k67iSR

As surprising as the picture posted below may be to some, IT IS TRUE. Averix Bio has successfully completed a 21 CFR Part 210 and Part 211 compliance audit conducted by the ProPharma Group. That means we now can provide cGMP-compliant API Phytocannabinoid CBD isolate for your research, clinical studies and products. You can trust that Averix is a science-driven manufacturer that minimizes your supply-chain risk and can help you explore the potential benefits of cannabinoid ingredients for patients.

We’re attending the CPhI conference in Milan and would welcome the opportunity to learn more about your company and answer any questions you may have about us, our products or the science supporting the use of cannabinoid ingredients.

Look forward to starting the conversation with you!

11/02/2021

If you want to know what it takes to help ensure that your customers can and will trust that your products contain safe and efficacious cannabinoid ingredients of the highest quality, read this post from our CEO, Miles Wright, and learn what cGMP 210/211 compliance is and why it must be a critical component of your supply chain:

READ NOW | https://averixbio.com/why_cgmp_matters/

And if you're looking for a 21 CFR Part 210 and Part 211 cGMP-compliant API Phytocannabinoid isolate, look no further. We successfully completed an independent audit by the ProPharma Group in October and are ready to be your trusted partner and Tier One supplier. Get in touch with us at hello@averixbio.com or +1 252.220.0887, and let's start the conversation.

**p

10/12/2021

Averix Bio is THRILLED to announce that we successfully completed an independent audit for 21 CFR PART 210 and PART 211 cGMP compliance of API Phytocannabinoid CBD isolate in the U.S. as well as for ICH Q7 standards! (API = Active Pharmaceutical Ingredient)

What does this mean? It means pharmaceutical, food and beverage, nutraceutical and cosmetic companies can now secure API Phytocannabinoid CBD isolate for their preclinical research, clinical trials and manufacturing. The compliance audit was conducted by the ProPharma Group, a leading global, independent, single-source provider of regulatory, clinical and compliance services serving pharmaceutical, biotechnology and medical device companies.

This is truly an historic milestone for Averix Bio, the biopharmaceutical sector and the CBD industry. Our goal has been and continues to be known as the ingredient partner of choice for manufacturers in multiple sectors looking for a Tier 1 supplier of trackable, transparent and trustworthy cannabinoid ingredients. Today’s announcement proves that goal can – and will – be achieved.

Congratulations and thank you to our Quality and Compliance team for their expertise, dedication and tireless work that made this possible. BRAVO!

Read our news release here: https://averixbio.com/news-averix-bio-a-botanical-based-cannabinoid-supplier-achieves-cgmp-21-cfr-part-210-and-part-211-and-ich-q7-compliance/

Get in touch with us at averixbio.com. We are ready to partner with you!

**p

09/29/2021

The Averix Bio team was excited to participate in the Fourth Annual International Cannabinoid Derived Pharmaceutical (iCDP) Summit last week in Boston. What a spectacular conference! It was truly invigorating to hear from so many researchers and scientists about the rapidly growing interest in exploring the health benefits of cGMP-compliant ingredients.

We especially enjoyed the presentation from Hunter Land, Vice President of Research and Development at Alterola Biotech Inc.: “Carrying Out Translational Studies in Cannabinoid Medicine.” Mr. Land discussed the vital guidelines that researchers must follow to ensure their clinical studies involving cannabinoid ingredients yield accurate, meaningful and safe results. As he noted, Alterola Biotech is focused on “harnessing the therapeutic potential of cannabinoids and cannabinoid-like compounds, which can bring valuable treatments to seriously ill patients.”

Averix Bio couldn’t agree more. As a 21 CFR Part 210 and Part 211 cGMP-compliant supplier of botanical-based API Phytocannabinoid CBD Isolate, we’re ready to be your trusted and transparent partner for your pre-clinical/clinical research and the medical therapies you want to bring to patients in need. Learn more at averixbio.com.

09/17/2021

Averix Bio is submitting a DMF for our CBD isolate to the in Q4 2021. What will that mean for you? In short, you’ll be able to partner with a 21 CFR PART 210 and PART 211 cGMP compliant supplier of botanical-based API for your pre-clinical/clinical research and medical therapies you bring to the global patient market. Come talk with us at the Summit in Boston next week and learn more.

Will's pharmaceutical experience spans nearly 50 years, with tenure at multinational companies like Burroughs Wellcome, , , , , and . He understands FDA Quality Systems Regulations, cGMPs, ISO Quality Systems standards, and ICH guidelines. He has both hosted and performed numerous FDA and third-party audits over the years. You can read Will’s thoughts about “The Q Word: What Quality Means at Averix Bio” in this post: https://averixbio.com/the-q-word/

09/13/2021

21 CFR Part 210 and Part 211 cGMP-compliant.
That means you can TRUST our botanical-based CBD isolate.
And that means you can TRUST Averix Bio.

Visit us during the Summit and learn about our 21 CFR Part 210 and Part 211 cGMP-compliant . We're ready to partner with you on early- to late-phase studies and therapeutic products for patients. https://www.averixbio.com

Address

3040 Black Creek Road South
Wilson, NC
27893

Website

https://www.averixbio.com/

Alerts

Be the first to know and let us send you an email when Averix Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Averix Bio:

Shortcuts

Want your practice to be the top-listed Clinic in Wilson?

We’re FDA Ready. Are You?

Make no mistake, the FDA is coming to the CBD industry and coming soon. Will your products be ready or will you disappear along with the countless CBD companies making inferior products in non-compliant facilities? Avient Biosciences manufactures certified food and pharmaceutical grade ingredients for companies in the consumer products industry that demand compliance and accountability from their suppliers.

Located on the East Coast and led by a world-class team of experts in the pharmaceutical, food, beverage, and cosmetic industries, we hold ourselves to a higher standard. At Avient we believe that the companies that rise to the top of the cannabinoid products industry will be those that demand complete transparency and safety in their products.

From South Carolina to South Africa to Southeast Asia—we're helping companies of all sizes future-proof their business by delivering cannabinoid ingredients that will stand up to the highest levels of regulation. We're FDA ready. Are you?